Overview

RAD001 Plus Carboplatin in Breast Cancer Patients

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study investigates the effectiveness of combination of carboplatin and investigational agent RAD001 in triple-negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Collaborator:
Novartis Pharmaceuticals
Treatments:
Carboplatin
Everolimus
Sirolimus